heparesc
cytonet gmbh kg - ljudske ćelije jetre гетерологичных - poremećaji ciklusa ureje, umrli - drugi gastrointestinalni trakt i metabolizam, lijekovi, - liječenje poremećaja ciklusa ureje (jcd), koji se.
azacitidine betapharm
betapharm arzneimittel gmbh - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - Азацитидин betapharm indiciran za liječenje odraslih bolesnika koji nemaju pravo na hematopoetski transplantacija matičnih stanica (ТГСК) s:middleware-2 i visokog rizika миелодиспластические sindroma (mds) prema međunarodnoj prognozu sustav bodovanja (ipss),kronični миеломоноцитарный leukemije (ХММЛ) od 10% do 29 % бластов koštane srži, bez миелопролиферативные poremećaja,akutnog миелоидного leukemije (aml) od 20% do 30 % бластов i multi-porijeklo displazije, prema podacima svjetske zdravstvene organizacije (who) za klasifikaciju aml s > 30 % бласты koštane srži prema klasifikaciji svjetske zdravstvene organizacije.
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
azacitidine accord
accord healthcare s.l.u. - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - Азацитидин akord indiciran za liječenje odraslih bolesnika koji nemaju pravo na hematopoetski transplantacija matičnih stanica (ТГСК) s:- middleware-2 i visokog rizika миелодиспластические sindroma (mds) prema međunarodnoj prognozu sustav bodovanja (ipss),- kronični миеломоноцитарный leukemije (ХММЛ) s 10-29 % mozgu бластов bez миелопролиферативные poremećaja, akutnog миелоидного leukemije (aml) s 20-30 % бластов i multi-porijeklo displazije, prema podacima svjetske zdravstvene organizacije (who) za klasifikaciju,- aml s >30% бласты koštane srži prema klasifikaciji svjetske zdravstvene organizacije.
polivy
roche registration gmbh - polatuzumab ведотин - limfom, b-stanični - antineoplastična sredstva - Полевий u kombinaciji s Бендамустин i rituksimab je indiciran za liječenje odraslih bolesnika s ponavljajućom/uporan da bi se raspršili u-крупноклеточной limfoma (ДВККЛ), koji nisu kandidati za transplantaciju гемопоэтических transplantacija matičnih stanica. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).
elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastična sredstva - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).
jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
trodelvy
gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastična sredstva - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.